Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
BQ.1.1.79NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.14NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FD.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CM.7NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.25.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
BQ.1.13.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBC.1.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GC.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26074.3US
XBB.1.5.40NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.1.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.32NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.1.65NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.10NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.1.38NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
DT.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
DS.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.1.63NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
DU.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.1.53NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BF.7.4.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-24753.3US
XBB.1.15NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.1.6NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.2.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CV.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBKNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.14.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBK.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EF.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CM.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
DF.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.1.35NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EH.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.3.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
DF.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CK.1.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.2.27NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-22683US
XBB.1.16.20NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.34.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JD.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.25NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.79NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HP.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FU.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EG.1.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.2.3.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EY.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used